The "Febrile Neutropenia - Global Clinical Trials Review, 2024" report has been added to ResearchAndMarkets.com's offering.The clinical trials report provides an overview of the Febrile Neutropenia ...

Nearly one year after winning an FDA drug approval to treat an ultra-rare disease, X4 Pharmaceuticals is making layoffs that ...

Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025Right-sizing commercial efforts to ...

Chemotherapy-induced neutropenia is a major risk factor for infection-related morbidity and mortality and an important dose-limiting toxicity in cancer treatment. The incidence of severe ...

Managing maximum tolerated dose (MTD) chemotherapy while minimizing neutropenia relies on precise complete blood count (CBC) monitoring and AI-powered diagnostics.

Objective: To systematically evaluate the literature to determine whether vancomycin-induced neutropenia is dose- or duration-related and provide clinicians with feasible treatment alternatives.

X4 Pharmaceuticals (XFOR) announced a restructuring of its workforce and capital spending to focus efforts on advancing mavorixafor to treat ...

Suggestions regarding when it is appropriate to initiate chemotherapy-induced neutropenia prophylaxis in patients with cancer and goals of therapy. January 18th 2021EP. 5: Chemotherapy-Induced ...

The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.